EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study

Alain Amstutz, Frédérique Chammartin, Annette Audigé, Anna L Eichenberger, Dominique L Braun, Patrizia Amico, Marcel P Stoeckle, Barbara Hasse, Matthaios Papadimitriou-Olivgeris, Oriol Manuel iD, Cédric Bongard, Macé M Schuurmans und 19 weitere

The Journal of Infectious Diseases · 2024

DOI: 10.1093/infdis/jiae291 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Alain Amstutz und 30 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Antibodies, Viral, COVID-19, COVID-19 Vaccines, Immunization, Secondary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Moderna, Swiss National Science Foundation, Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bivalent messenger RNA (mRNA) vaccines, designed to combat emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, incorporate ancestral strains and a new variant. Our study assessed the immune response in previously vaccinated individuals of the Swiss HIV Cohort Study (SHCS) and the Swiss Transplant Cohort Study (STCS) following bivalent mRNA vaccination.

Methods

Eligible SHCS and STCS participants received approved bivalent mRNA SARS-CoV-2 vaccines (mRNA-1273.214 or BA.1-adapted BNT162b2) within clinical routine. Blood samples were collected at baseline, 4 weeks, 8 weeks, and 6 months postvaccination. We analyzed the proportion of participants with anti-spike protein antibody response ≥1642 units/mL (indicating protection against SARS-CoV-2 infection), and in a subsample T-cell response (including mean concentrations), stratifying results by cohorts and population characteristics.

Results

In SHCS participants, baseline anti-spike antibody concentrations ≥1642 units/mL were observed in 87% (96/112), reaching nearly 100% at follow-ups. Among STCS participants, 58% (35/60) had baseline antibodies ≥1642 units/mL, increasing to 80% at 6 months. Except for lung transplant recipients, all participants showed a 5-fold increase in geometric mean antibody concentrations at 4 weeks and a reduction by half at 6 months. At baseline, T-cell responses were positive in 96% (26/27) of SHCS participants and 36% (16/45) of STCS participants (moderate increase to 53% at 6 months). Few participants reported SARS-CoV-2 infections, side-effects, or serious adverse events.

Conclusions

Bivalent mRNA vaccination elicited a robust humoral response in individuals with human immunodeficiency virus (HIV) or solid organ transplants, with delayed responses in lung transplant recipients. Despite a waning effect, antibody levels remained high at 6 months and adverse events were rare. Clinical Trials Registration . NCT04805125.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, ViralCOVID-19COVID-19 VaccinesImmunization, SecondarySARS-CoV-2T-LymphocytesAdultAgedFemaleHumansMaleMiddle Aged2019-nCoV Vaccine mRNA-1273Antibodies, NeutralizingBNT162 VaccineCohort StudiesHIV InfectionsImmunocompromised HostSpike Glycoprotein, CoronavirusSwitzerland

Stichwörter der Autor:innen

HIVSARS-CoV-2bivalent vaccineorgan transplantvaccine

Substanzen

2019-nCoV Vaccine mRNA-1273Antibodies, NeutralizingAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesSpike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • Division of Clinical Epidemiology, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Oslo Center for Biostatistics and Epidemiology, Oslo University Hospital, University of Oslo, Oslo, Norway.
  • Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
  • Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.

ORCID-Profile: Oriol Manuel, Andri Rauch, Huldrych F Günthard, Alexandra Trkola, Katharina Kusejko, Matthias Briel, Benjamin Speich

Förderung

  • Moderna
  • Swiss National Science Foundation
  • Roche
  • University of Basel
  • Janggen Pöhn Foundation

Zitieren

APA

Amstutz, A., Chammartin, F., Audigé, A., Eichenberger, A. L., Braun, D. L., Amico, P., Stoeckle, M. P., Hasse, B., Papadimitriou-Olivgeris, M., Manuel, O., Bongard, C., Schuurmans, M. M., Hage, R., Damm, D., Tamm, M., Mueller, N. J., Rauch, A., Günthard, H. F., Koller, M. T., …, & Swiss Transplant Cohort (2024). Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae291

Vancouver

Amstutz A, Chammartin F, Audigé A, Eichenberger AL, Braun DL, Amico P, et al. Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae291

BibTeX
@article{Amstutz2024,
  author = {Amstutz, Alain and Chammartin, Frédérique and Audigé, Annette and Eichenberger, Anna L and Braun, Dominique L and Amico, Patrizia and Stoeckle, Marcel P and Hasse, Barbara and Papadimitriou-Olivgeris, Matthaios and Manuel, Oriol and Bongard, Cédric and Schuurmans, Macé M and Hage, René and Damm, Dominik and Tamm, Michael and Mueller, Nicolas J and Rauch, Andri and Günthard, Huldrych F and Koller, Michael T and Schönenberger, Christof M and Griessbach, Alexandra and Labhardt, Niklaus D and Kouyos, Roger D and Trkola, Alexandra and Kusejko, Katharina and Bucher, Heiner C and Abela, Irene A and Briel, Matthias and Speich, Benjamin and Swiss HIV Cohort Study, Swiss HIV Cohort Study and Swiss Transplant Cohort, Swiss Transplant Cohort},
  title = {Antibody and T-Cell Response to Bivalent Booster SARS-CoV-2 Vaccines in People With Compromised Immune Function: COVERALL-3 Study},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1093/infdis/jiae291}
}
Kostenlos starten →